Portal de Periódicos da CAPES

Second-Line Antiretroviral Treatment Successfully Resuppresses Drug-Resistant HIV-1 After First-Line Failure: Prospective Cohort in Sub-Saharan Africa

2012; Oxford University Press; Volume: 205; Issue: 11 Linguagem: Inglês

10.1093/infdis/jis261

1537-6613

Kim Sigaloff, Raph L Hamers, Carole L. Wallis, Cissy Kityo, Margaret Siwale, Prudence Ive, M. E. Botes, Kishor Mandaliya, Melanie Wellington, Akin Osibogun, Wendy Stevens, Michèle van Vugt, Tobias F. Rinke de Wit,

HIV/AIDS Research and Interventions

Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53% were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.